Table 3.
Number of Patients and Absolute Risk of Discontinuation by Sociodemographic Category
| Sociodemographic Group | Number of Patients (N) | AR-D Crude (%) | AR-D Adjusteda (%) |
|---|---|---|---|
| 65–80 male high | 3530 | 17.65 | 16.71 |
| 65–80 male middle | 5913 | 17.74 | 17.07 |
| 65–80 male low | 5731 | 18.79 | 18.22 |
| 50–64 male high | 1528 | 21.53 | 20.59 |
| 50–64 male middle | 1831 | 24.30 | 23.39 |
| 50–64 male low | 2288 | 26.79 | 25.61 |
| 35–49 male high | 115 | 29.57 | 26.54 |
| 35–49 male middle | 161 | 34.78 | 31.58 |
| 35–49 male low | 347 | 36.60 | 34.05 |
| 65–80 female high | 3555 | 14.74 | 13.81 |
| 65–80 female middle | 7070 | 15.30 | 14.56 |
| 65–80 female low | 7813 | 15.33 | 14.85 |
| 50–64 female high | 2026 | 15.20 | 14.55 |
| 50–64 female middle | 2904 | 17.84 | 17.24 |
| 50–64 female low | 3091 | 21.51 | 20.72 |
| 35–49 female high | 68 | 23.53 | 21.79 |
| 35–49 female middle | 214 | 32.24 | 29.58 |
| 35–49 female low | 834 | 31.77 | 30.46 |
| Total | 49,019 | 18.36 | 21.86 |
Notes: Number of patients by sociodemographic group, as well as crude and adjusted absolute risk for discontinuation (AR-D) of inhaled maintenance medication in 2011. Values are percentages if not otherwise indicated. aEstimated from the cross-classified MAIHDA.